Additionally, the use of osimertinib as adjuvant therapy in operable EGFR-mutated NSCLC[28], as neoadjuvant therapy in advanced EGFR-mutated NSCLC[27], and in combination therapies[120] may induce greater heterogeneity and more complex resistance mechanisms. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.